memantine - CAS 19982-08-2
Catalog number: 19982-08-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
NMDA Receptor
memantine, also called Namenda, a N-methyl D-aspartate (NMDA) antagonist prescribed to treat symptoms of moderate to severe Alzheimer's, blocks the toxic effects associated with excess glutamate and regulates glutamate activation
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
A N-methyl-D-aspartate Receptor Antagonist
White solid
3,5-dimethyladamantan-1-amine; memantine; 3,5-dimethyladamantan-1-amine; 19982-08-2; 1-Amino-3,5-dimethyladamantane; Memantina; Memantinum; Namenda; Ebixa; Memantin; Memantinum [INN-Latin]; 3,5-Dimethyl-1-adamantylamine; Memantina [INN-Spanish]; 1,3-Dimethyl-5-adamantanamine; 3,5-Dimethyl-1-adamantanamine; CHEMBL807; UNII-W8O17SJF3T; Memantine (INN); Memantine [INN]; Exiba (TN); 3,5-Dimethyl-1-aminoadamantan
Soluble in DMSO
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
Boiling Point:
266.6°C at 760 mmHg
1.046 g/cm3
Canonical SMILES:
1.A Review of Pharmacologic Treatment for Compulsive Buying Disorder.
Soares C1, Fernandes N2, Morgado P2,3,4. CNS Drugs. 2016 Apr 11. [Epub ahead of print]
At present, no treatment recommendations can be made for compulsive buying disorder. Recent studies have found evidence for the efficacy of psychotherapeutic options, but less is known regarding the best pharmacologic treatment. The purpose of this review is to present and analyze the available published evidence on the pharmacological treatment of compulsive buying disorder. To achieve this, we conducted a review of studies focusing on the pharmacological treatment of compulsive buying by searching the PubMed/MEDLINE database. Selection criteria were applied, and 21 studies were identified. Pharmacological classes reported included antidepressants, mood stabilizers, opioid antagonists, second-generation antipsychotics, and N-methyl-D-aspartate receptor antagonists. We found only placebo-controlled trials for fluvoxamine; none showed effectiveness against placebo. Three open-label trials reported clinical improvement with citalopram; one was followed by a double-blind discontinuation.
2.Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease.
Prati F1,2, Cavalli A3,4, Bolognesi ML5. Molecules. 2016 Apr 8;21(4). pii: E466. doi: 10.3390/molecules21040466.
Multitarget drug discovery is one of the hottest topics and most active fields in the search for new molecules against Alzheimer's disease (AD). Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clinical level. However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists. This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties. In this respect, large hybrid molecules and small fragments are poles apart. In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like molecules directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β). In addition, we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clinical studies.
3.Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.
Lauterbach EC1. Am J Neurodegener Dis. 2016 Mar 1;5(1):29-51. eCollection 2016.
Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of neurodegeneration in MCI and early PD via inflammatory mechanisms and the generation of degenerative proinflammatory cytokines. Psychiatric disorders, prevalent in AD and PD, are often treated with psychiatric drugs (psychotropics), raising the question of whether psychotropics might therapeutically affect microglial activation, MCI, and PD. The literature of common psychotropics used in treating psychiatric disorders was reviewed for preclinical and clinical findings regarding microglial activation. Findings potentially compatible with reduced microglial activation or reduced microglial inflammogen release were evident for: antipsychotics including neuroleptics (chlorpromazine, thioridazine, loxapine) and atypicals (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone); mood stabilizers (carbamazepine, valproate, lithium); antidepressants including tricyclics (amitriptyline, clomipramine, imipramine, nortriptyline), SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), venlafaxine, and bupropion; benzodiazepine anxiolytics (clonazepam, diazepam); cognitive enhancers (donepezil, galantamine, memantine); and other drugs (dextromethorphan, quinidine, amantadine).
4.Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.
Bhakta SG1, Chou HH1, Rana B1, Talledo JA1, Balvaneda B1, Gaddis L1, Light GA1, Swerdlow NR2. Psychopharmacology (Berl). 2016 Apr 13. [Epub ahead of print]
RATIONALE: Pro-cognitive agents for chronic psychotic disorders (CPDs) might be detected via experimental medicine models, in which neural targets engaged by the drug predict sensitivity to the drug's pro-cognitive effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 19982-08-2 memantine

Quick Inquiry

Verification code

Featured Items